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IMPORTANCE Patients diagnosed with localized prostate cancer have to decide among
treatment strategies that may differ in their likelihood of adverse effects.
OBJECTIVE To compare quality of life (QOL) after radical prostatectomy, external beam
radiotherapy, and brachytherapy vs active surveillance.
DESIGN, SETTING, AND PARTICIPANTS Population-based prospective cohort of 1141men (57%
participation among eligible men) with newly diagnosed prostate cancer were enrolled from
January 2011 through June 2013 in collaboration with the North Carolina Central Cancer
Registry. Median time from diagnosis to enrollment was 5 weeks, and all men were enrolled
with written informed consent prior to treatment. Final follow-up date for current analysis
was September 9, 2015.
EXPOSURES Treatment with radical prostatectomy, external beam radiotherapy,
brachytherapy, or active surveillance.
MAIN OUTCOMES ANDMEASURES Quality of life using the validated instrument Prostate
Cancer Symptom Indices was assessed at baseline (pretreatment) and 3, 12, and 24months
after treatment. The instrument contains 4 domains—sexual dysfunction, urinary
obstruction and irritation, urinary incontinence, and bowel problems—each scored from0
(no dysfunction) to 100 (maximum dysfunction). Propensity-weightedmean domain scores
were compared between each treatment group vs active surveillance at each time point.
RESULTS Of 1141 enrolled men, 314 pursued active surveillance (27.5%), 469 radical
prostatectomy (41.1%), 249 external beam radiotherapy (21.8%), and 109 brachytherapy
(9.6%). After propensity weighting, median age was 66 to 67 years across groups, and 77%
to 80% of participants were white. Across groups, propensity-weightedmean baseline
scores were 41.8 to 46.4 for sexual dysfunction, 20.8 to 22.8 for urinary obstruction and
irritation, 9.7 to 10.5 for urinary incontinence, and 5.7 to 6.1 for bowel problems. Compared
with active surveillance, mean sexual dysfunction scores worsened by 3months for patients
who received radical prostatectomy (36.2 [95% CI, 30.4-42.0]), external beam radiotherapy
(13.9 [95% CI, 6.7-21.2]), and brachytherapy (17.1 [95% CI, 7.8-26.6]). Compared with active
surveillance at 3 months, worsened urinary incontinence was associated with radical
prostatectomy (33.6 [95% CI, 27.8-39.2]); acute worsening of urinary obstruction and
irritation with external beam radiotherapy (11.7 [95% CI, 8.7-14.8]) and brachytherapy
(20.5 [95% CI, 15.1-25.9]); and worsened bowel symptoms with external beam radiotherapy
(4.9 [95% CI, 2.4-7.4]). By 24months, mean scores between treatment groups vs active
surveillance were not significantly different in most domains.
CONCLUSIONSANDRELEVANCE In this cohort ofmenwith localizedprostate cancer, each
treatment strategywas associatedwithdistinct patternsof adverse effects over 2 years. These
findings canbeused topromote treatmentdecisions that incorporate individual preferences.
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T he comparative effectiveness of contemporary treat-ment options for localized prostate cancer is one of thehighest priority research questions according to the
National Academy of Medicine (previously the Institute of
Medicine).1 Because patients with prostate cancer often have
extended life expectancy, the quality-of-life (QOL) effects of
different treatment options is a central consideration for
many men in their decision-making process.
Since the mid-2000s, technologic advances in surgical
and radiation treatments—eg, robotic prostatectomy and
intensity-modulated radiotherapy—have been rapidly dis-
seminated in clinical practice.2,3 These new technologies
were developed with a primary purpose to reduce treatment-
related morbidity rather than improve cure. Studies showed
that surgery and radiotherapy can cause sexual, urinary, and
bowel dysfunction4; however, it is unclear whether contem-
porary technologies cause the same magnitude of problems.
In addition, with increasing recognition that many patients
may not need treatment immediately, active surveillance is
now a standard option,5 which preserves QOL for an
unknown period for each man, until treatment is needed at
the time of cancer progression.
The North Carolina Prostate Cancer Comparative Effec-
tiveness & Survivorship Study (NC ProCESS) is a population-
based,observational cohortofmenwithnewlydiagnosedpros-
tate cancer who were all enrolled prior to treatment and
followed prospectively. The purpose of this studywas to ana-
lyzeQOLchanges frombaseline (pretreatment) through2years
after treatment for men who received radical prostatectomy,
external beam radiotherapy, or brachytherapy vs those who
pursued active surveillance.
Methods
This study was approved by the University of North Carolina
institutional review board. Patients were recruited in col-
laboration with the Rapid Case Ascertainment system of the
North Carolina Central Cancer Registry (NCCCR). All partici-
pants signed written informed consent. The NCCCR achieves
the highest North American Association of Central Cancer
Registries standard for complete and accurate cancer inci-
dence data (gold certificate), with more than 95% data com-
pleteness and 100% error-free data on cancer type, sex, race,
and age. NCCCR does not collect data on adverse effects.
Rapid Case Ascertainment is an accelerated incident report-
ing process in which registry staff proactively obtain informa-
tion regarding tumors relevant to the study from local hospi-
tals and facilities throughout all 100 counties of the state.
This system allowed completion of baseline survey a median
of 5 weeks after diagnosis.
Data Collection
Demographics—age, race, insurance, education, household
income, marital status—were assessed by patient report on
the baseline survey. Race was collected in fixed categories
to assess diversity of the cohort and also used as part of pro-
pensity score calculations to adjust for potential differences
across comparison groups. Treatments received and dates
were determined by medical record abstraction; if a medical
record was unavailable, then cancer registry data were used.
Because the primary goal of this study was to inform
patients’ initial treatment decision making, treatment group
assignment for data analysis was based on the initial treat-
ment received (eg, men who first received a prostatectomy
and subsequently received an additional salvage treatment
were categorized in the prostatectomy group). Active sur-
veillance was defined with medical records stating this as
the plan.
Outcomes
QOLwas assessed using the validated Prostate Cancer Symp-
tom Indices (PCSI)6; all surveys were conducted by tele-
phone similar to prior methodology,7 at baseline (pretreat-
ment) and 3, 12, and 24 months after the treatment date. For
active surveillance, an anchor date was assigned as 3months
after diagnosis for purposes of calculating subsequent survey
dates. Each participant at each time point was called up to
10 times over a 3-week period (including evening and week-
end times) tomaximize response.Date of the last surveyused
in the current analysis was September 9, 2015.
The PCSI has 4 domains: urinary obstruction and irrita-
tion (5 items), urinary incontinence (3 items), sexual dysfunc-
tion (5 items), and bowel problems (6 items). Each domain is
scored from 0 to 100, with a higher score indicating more or
worse dysfunction. Minimal clinically important differences
for PCSI domains have not been defined. Parallel to each
of the 4 domains are additional questions which ask pa-
tients about the magnitude of bother related to urinary
obstruction and irritation, urinary incontinence, sexual, and
bowel symptoms. In addition to numerical scoring for each
domain described above, the PCSI has established functional
levels (normal, intermediate, and poor) that incorporate the
symptom as well as bother questions.8,9 These function lev-
els complement the score reporting because QOL score
changes are well recognized to be difficult for patients and
physicians to interpret.10 Normal function describes a patient
with essentially no dysfunction or distress in a domain11,12
Key Points
Question What differences in quality of life are associated with
radical prostatectomy, external beam radiotherapy, brachytherapy,
and active surveillance after treatment for prostate cancer?
Findings In this population-based, prospective cohort of 1141 men
diagnosed from January 2011 through June 2013, radical
prostatectomywas associated with worse sexual dysfunction and
urinary incontinence compared with active surveillance, external
beam radiotherapy and brachytherapy with worse short-term
urinary obstruction and irritation, and external beam radiotherapy
with worse short-term bowel symptoms. However, by 24months,
mean scores between treatment groups vs active surveillance
were not significantly different in most domains.
Meaning Contemporary treatment strategies were associated
with distinct patterns of adverse effects over 2 years.
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(eg, normal function in the urinary incontinence domain
describes a man who has full urinary control without inconti-
nence). Intermediate function describes a patient with
at least 1 distressful symptom but none very distressful
(eg, intermediate urinary incontinence represents leaking
only at certain times, and no more than a few drops). Poor
function describes patients with at least 1 very distressful
symptom (eg, poor sexual function represents no erections
capable of intercourse or a lot of difficulty getting and keep-
ing an erection). This classification adds clinical meaning to
numerical scores, and also allowed analysis of QOL outcomes
stratified by each participant’s baseline level.9 Effect sizes
between functional levels of the PCSI are large.9,12
Data Analysis
To adjust for potentially important differences in baseline
characteristics across cohorts, propensity scores were esti-
mated separately for each of the 3 treatment types (external
beam radiotherapy, brachytherapy, and prostatectomy) vs
active surveillance. Propensity scores were obtained from the
predicted probabilities in separate logistic regression models
contrasting active surveillance against each of the 3 treat-
ment types. Variables included in the regression models were
race, insurance, marital status, education, income, year of
diagnosis, age at diagnosis, and baseline 12-Item Short Form
Survey (SF-12) and PCSI domain scores. Using the propensity
scores, all patients in the 3 treatment groups were assigned
weights from their propensity scores odds [propensity
scores / (1 − propensity scores)], whereas patients in active
surveillance each received a weight of 1.13 This methodology
balances the observed covariate distribution between the
treatment groups relative to active surveillance allowing
comparison of each treatment group’s QOL outcomes against
active surveillance.14 Standardized differences15 were calcu-
lated to compare the distributions of covariates between the
cohorts both before and after propensity score–weighting to
assess that the covariate balancing adequately addressed
measured confounding across cohorts.
Propensity-weightedQOLscores foreachPCSIdomainwas
calculated for eachparticipant at each timepoint.Missingdata
at 3, 12, and 24monthsweremultiply imputedusing the fully
conditional specification approach.13,16 Multiple imputation
was separately run for each of 4 domains within each treat-
ment group for men with nonmissing data at baseline. This
method sequentially regressed an outcome on the immedi-
ately precedingoutcome (timepoint) score andbaseline char-
acteristics and replaced the missing values with values from
observed (nonmissing) data that were closest to the model-
predictedvalue for the respective observation. To account for
potential nonindependence due to weighting, robust stan-
dard errorswere used in the computation of 95%CIs from the
imputed data sets. To account for uncertainty occurring due
to imputation, final estimates were derived by pooling esti-
mates fromall imputeddata sets.MissingQOL functional lev-
elswere also imputed using a similar approach. Ordinal logis-
tic regression was used to impute missing levels using the
preceding timepoint functional level andQOLscore andbase-
line characteristics as variables.
The primary goal of this study was to compare the
domain scores of each treatment group (external beam radio-
therapy, brachytherapy, prostatectomy) with those of active
surveillance. We used an established convention17-19 to
denote clinically meaningful differences in scores as those
which exceed 0.5 standard deviation of the baseline score of
the active surveillance (control) group. In addition to analy-
ses of the overall cohort, stratified subgroup analyses based
on patients’ baseline QOL level in each domain were per-
formed to assess if treatments differentially affected men
who had different levels of baseline QOL.
All tests had a 2-sided P value of less than .05 for statisti-
cal significance. Analyses were performed using SAS (SAS In-
stitute), version 9.4.
Results
From January 2011 through June 2013, 1419 men with local-
ized prostate cancer who had not yet started treatment
were enrolled; this represents 57% participation among eli-
gible men.20 Participants vs nonparticipants were younger
(median age, 65 years vs 68 years), with nonsignificantly dif-
ferent Gleason scores and race.20 Among enrolled men, 69
did not receive any of the 4 modalities to be compared in
this analysis, and an additional 209 did not complete any
follow-up survey. Therefore, this analysis included a final
sample of 1141 men.
Among 1141 men, 314 received active surveillance
(27.5%), 249 external beam radiotherapy (21.8%), 109 brachy-
therapy (9.6%), and 469 prostatectomy (41.1%) (Table 1).
Among those who received external beam radiotherapy,
94.8% received intensity-modulated radiotherapy, and 70.7%
had image guidance. Among those who received radical pros-
tatectomy, 86.6% received robotic surgery. Participants were
sociodemographically diverse in race, education, and in-
come. Patients who received prostatectomy were younger
and had better baseline QOL than patients who received
radiotherapy. Differences in baseline demographic character-
istics and QOL were minimized with propensity weighting.
After propensity weighting, median age was 66 to 67 years
across groups, and 77% to 80% of participants were white.
Missingdata inQOLare detailed in eTable 1 in the Supple-
ment. At 24months, there wasmissing data in 19% to 29% of
participants across groups and QOL domains.
Sexual Dysfunction
Propensity-weighted mean domain scores across the 4
groups at each time point were summarized in Table 2. Sensi-
tivity analysis, which included the 209 patients with baseline
but no follow-up survey data, are shown in eTable 2 in the
Supplement. At baseline, propensity-weighted scores were
43.4 (95% CI, 39.2-47.6) for active surveillance, 41.8 (95% CI,
36.3-47.2) for external beam radiotherapy, 46.4 (95% CI, 36.1-
56.7) for brachytherapy, and 41.6 (95% CI, 35.6-47.6) for pros-
tatectomy. Mean scores for the active surveillance group
increased gradually over time. At 3 and 12 months but not 24
months, patients who received external beam radiotherapy
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Table 1. Patient Demographics and Baseline Characteristics AmongMenWith Newly Diagnosed Prostate Cancer
Before Propensity Weighting, No. (%) After Propensity Weighting, %
Active
Surveillance
(n = 314)
External
Beam RT
(n = 249)
Brachytherapy
(n = 109)
Radical
Prostatectomy
(n = 469)
Active
Surveillancea
External
Beam RT Brachytherapy
Radical
Prostatectomy
Age at diagnosis,
mean (SD), y
67 (7.3) 67 (7.1) 66 (7.3) 62 (6.8) 67 (7.3) 67 (7.3) 67 (7.6) 66 (7.3)
Race
White 242 (77) 154 (62) 82 (75) 347 (74) 77 79 77 80
African American 69 (22) 84 (34) 26 (24) 111 (24) 22 19 20 19
Other 3 (1) 11 (4) 1 (1) 11 (2) 1 2 3 2
Health insurance
Medicare 156 (50) 134 (54) 58 (53) 139 (30) 50 50 51 51
Private 94 (30) 61 (25) 31 (28) 246 (53) 30 30 28 30
Medicaid/None 64 (20) 54 (22) 20 (18) 84 (18) 20 20 21 19
Education
≤High school 93 (30) 99 (40) 42 (38) 131 (28) 30 28 29 29
Some college 86 (27) 71 (29) 35 (32) 138 (29) 27 29 27 27
College graduate 135 (43) 79 (32) 32 (29) 200 (43) 43 43 44 44
Household income, $ yearly
<40000 117 (37) 128 (51) 51 (47) 139 (30) 37 35 36 34
40000-70000 88 (28) 64 (26) 35 (32) 129 (28) 28 29 32 27
>70000-90000 44 (14) 23 (9) 13 (12) 69 (15) 14 15 13 15
>90000 65 (21) 34 (14) 10 (9) 132 (28) 21 20 19 23
Married 257 (82) 184 (74) 93 (85) 372 (79) 82 82 79 78
Baseline QOL Scores, Mean (SD)
SF-12b
Physical 48.7 (10.6) 48.1 (11.0) 49.9 (9.6) 51.2 (9.8) 48.7 (10.6) 48.8 (11.2) 48.9 (9.7) 49.7 (9.9)
Mental 55.2 (7.7) 53.1 (9.7) 54.7 (8.2) 52.2 (9.5) 55.2 (7.7) 55.4 (7.9) 55.5 (7.9) 55.5 (7.9)
PCSIc
Sexual dysfunction 43.4 (37.6) 51.1 (39.5) 46.5 (38.7) 35.6 (36.6) 43.4 (37.6) 41.8 (39.5) 46.4 (40.1) 41.6 (38.0)
Urinary obstruction
and irritation
22.8 (13.5) 23.6 (15.5) 17.7 (10.2) 22.9 (14.2) 22.8 (13.5) 22.3 (14.8) 20.8 (10.5) 22.6 (13.6)
Urinary incontinence 10.4 (20.4) 13.0 (22.1) 6.2 (14.8) 7.9 (16.7) 10.4 (20.4) 9.9 (19.7) 10.5 (20.8) 9.7 (18.4)
Bowel problems 5.9 (8.0) 7.2 (10.7) 5.0 (7.6) 5.8 (8.4) 5.9 (8.0) 5.7 (8.5) 6.1 (7.5) 6.2 (8.0)
Patients with normal
baseline PCSI function
Sexual dysfunction 90 (29.0) 54 (21.8) 26 (24.5) 167 (35.9) 29.0 31.3 27.1 28.1
Urinary obstruction
and irritation
68 (22.3) 58 (23.5) 36 (34.3) 125 (27.1) 22.3 25.9 30.7 24.1
Urinary incontinence 226 (73.9) 169 (69.3) 86 (81.9) 360 (78.1) 73.9 76.4 75.6 74.8
Bowel problems 134 (43.2) 99 (40.1) 52 (49.1) 205 (44.3) 43.2 44.3 36.6 42.4
Variables Not Included in Propensity Score Calculation
PSA, ng/mL
0-9.9 273 (89.2) 184 (74.8) 97 (90.7) 407 (87.2) 89.2 80.1 91.8 87.3
10-20 19 (6.2) 35 (14.2) 8 (7.5) 40 (8.6) 6.2 11.9 6.5 7.2
>20 14 (4.6) 27 (11.0) 2 (1.9) 20 (4.3) 4.6 8.0 1.7 5.5
Biopsy Gleason score
≤6 268 (86.2) 88 (35.8) 84 (79.2) 213 (45.6) 86.2 39.2 72.7 46.8
7 41 (13.2) 121 (49.2) 21 (19.8) 207 (44.3) 13.2 46.5 23.1 41.6
8-10 2 (0.6) 37 (15.0) 1 (0.9) 47 (10.1) 0.6 14.4 4.2 11.6
Clinical stage
T1 276 (88.7) 179 (72.8) 94 (87.9) 348 (74.4) 88.8 73.2 79.2 71.8
T2 35 (11.3) 61 (24.8) 13 (12.1) 114 (24.4) 11.3 24.9 20.8 26.8
T3 or T4 0 6 (2.4) 0 6 (1.3) 0 1.9 0 1.5
Abbreviations: IQR, interquartile range; PCSI, prostate cancer
symptom indices; PSA, prostate-specific antigen; QOL, quality of life;
RT, radiotherapy.
a Propensity weight for active surveillance was set as 1.
b SF-12 Mental and Physical Function: scores range 0-100, with higher score
indicating better quality of life.
c PCSI domain6 scores range 0-100, with higher score indicating more
symptoms and dysfunction. Minimally clinically important difference not
defined for this instrument.
Research Original Investigation Association Between Prostate Cancer Treatment and Quality of Life
1144 JAMA March 21, 2017 Volume 317, Number 11 (Reprinted) jama.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2017 American Medical Association. All rights reserved.
and brachytherapy had increased sexual dysfunction com-
pared with active surveillance (between-group score differ-
ence: external beam radiotherapy vs active surveillance, 13.9
[95% CI, 6.7-21.2] at 3 months and 10.2 [95% CI 3.1-17.1] at 12
months; brachytherapy vs active surveillance, 17.1 [95% CI,
7.8-26.6] at 3 months and 14.3 [95% CI, 4.6-24.0] at 12
months); however, these differences did not meet the thresh-
old for clinical significance. eTable 3 in the Supplement
details sexual dysfunction scores in subgroups of patients
who received external beam radiotherapy alone and external
beam radiotherapy plus androgen deprivation therapy. The
between-group score difference for prostatectomy vs active
surveillance met the threshold for clinical significance (36.2
[95% CI, 30.4-42.0] at 3 months and 27.6 [95% CI, 21.8-33.4]
at 12 months).
Table 3 summarizedpropensity-weighted results stratify-
ingparticipantsbybaseline sexual function level.Formenwho
reportednormalbaseline sexual function, 57.1%reportedpoor
function at 24months after prostatectomy, 27.2%after exter-
nal beamradiotherapy, 34.2%after brachytherapy, and25.2%
after active surveillance. Formenwith intermediate baseline
function, larger proportions reported poor function at 24
months:76.9%afterprostatectomy,55.0%afterexternalbeam
radiotherapy,50.6%afterbrachytherapy,and45.9%afteractive
Table 2. Propensity-Weighted Prostate Cancer Symptom Indices Scores for Sexual, Urinary, and Bowel SymptomsOver Time Across Different
Treatment Groups AmongMenWith Newly Diagnosed Prostate Cancera
Active Surveillanceb External Beam Radiotherapy Brachytherapy Radical Prostatectomy
No. of
Patientsc
Mean Score
(95% CI)
No. of
Patientsc
Mean Score
(95%CI)
Mean
Difference
Score
vs Active
Surveillance
(95%CI)
No. of
Patientsc
Mean Score
(95%CI)
Mean
Difference
Score
vs Active
Surveillance
(95% CI)
No. of
Patientsc
Mean Score
(95%CI)
Mean
Difference
Score
vs Active
Surveillance
(95% CI)
Sexual Dysfunction
Baseline 310 43.4
(39.2 to 47.6)
248 41.8
(36.3 to 47.2)
−1.6
(−8.5 to 5.2)
106 46.4
(36.1 to 56.7)
3.0
(−8.1 to 14.1)
465 41.6
(35.6 to 47.6)
−1.8
(−9.1 to 5.5)
3 mo 299 44.6
(40.2 to 48.9)
229 58.5
(52.7 to 64.2)
13.9
(6.7 to 21.2)
107 61.7
(53.4 to 70.1)
17.1
(7.8 to 26.6)
440 80.8
(77.0 to 84.6)
36.2
(30.4 to 42.0)d
12 mo 272 48.1
(43.8 to 52.4)
215 58.2
(52.7 to 63.7)
10.2
(3.1 to 17.1)
96 62.4
(53.9 to 70.9)
14.3
(4.6 to 24.0)
414 75.7
(71.8 to 79.6)
27.6
(21.8 to 33.4)d
24 mo 229 56.6
(52.1 to 61.0)
187 59.2
(53.6 to 64.7)
2.6
(−4.8 to 10.0)
78 61.6
(53.5 to 69.7)
5.0
(−4.2 to 14.2)
375 73.7
(69.2 to 78.1)
17.1
(10.9 to 23.3)
Urinary Obstruction and Irritation
Baseline 307 22.8
(21.2 to 24.3)
248 22.3
(20.3 to 24.4)
−0.5
(−3.0 to 2.2)
107 20.8
(18.3 to 23.3)
−2.0
(−4.9 to 1.0)
465 22.6
(21.1 to 24.2)
−0.2
(−2.3 to 2.1)
3 mo 298 23.2
(21.7 to 24.6)
234 34.9
(32.2 to 37.6)
11.7
(8.7 to 14.8)d
104 43.7
(38.4 to 48.9)
20.5
(15.1 to 25.9)d
431 27.3
(25.4 to 29.1)
4.1
(1.7 to 6.5)
12 mo 278 26.2
(24.4 to 27.9)
217 23.9
(21.7 to 26.1)
−2.3
(−5.1 to 0.6)
93 31.7
(27.0 to 36.4)
5.5
(0.4 to 10.6)
417 21.9
(20.0 to 23.7)
−4.3
(−6.9 to −1.7)
24 mo 222 25.3
(23.5 to 27.1)
188 23.0
(20.7 to 25.2)
−2.3
(−5.2 to 0.6)
80 28.2
(24.4 to 32.0)
2.9
(−1.3 to 7.0)
376 19.6
(17.8 to 21.4)
−5.7
(−8.2 to −3.1)
Urinary Incontinence
Baseline 308 10.4
(8.2 to 12.8)
241 9.9
(7.5 to 12.4)
−0.6
(−3.9 to 2.8)
108 10.5
(3.8 to 17.2)
0
(−7.1 to 7.1)
462 9.7
(7.2 to 12.2)
−0.8
(−4.2 to 2.6)
3 mo 301 12.0
(9.7 to 14.4)
227 15.6
(12.3 to 19.0)
3.6
(−0.5 to 7.7)
107 18.1
(12.5 to 23.7)
6.1
(0 to 12.2)
406 45.6
(40.3 to 50.8)
33.6
(27.8 to 39.2)d
12 mo 276 14.1
(11.4 to 16.7)
216 15.3
(11.9 to 18.6)
1.2
(−3.1 to 5.5)
95 13.9
(8.6 to 19.3)
−0.2
(−6.2 to 5.9)
413 32.3
(27.7 to 36.9)
18.2
(12.9 to 23.5)d
24 mo 226 17.6
(14.6 to 20.6)
190 16.6
(13.3 to 20.0)
−1.0
(−5.5 to 3.6)
79 15.3
(9.9 to 20.8)
−2.3
(−8.5 to 3.9)
374 33.0
(27.2 to 38.8)
15.4
(8.9 to 21.9)d
Bowel Problems
Baseline 314 5.9
(5.0 to 6.8)
246 5.7
(4.6 to 6.7)
−0.2
(−1.6 to 1.1)
109 6.1
(4.5 to 7.6)
0.2
(−1.6 to 2.0)
467 6.2
(5.2 to 7.3)
0.3
(−1.1 to 1.7)
3 mo 302 7.1
(6.0 to 8.2)
235 12.0
(9.8 to 14.3)
4.9
(2.4 to 7.4)d
108 9.0
(6.9 to 11.1)
1.9
(−0.5 to 4.3)
444 6.7
(5.5 to 7.8)
−0.4
(−2.0 to 1.2)
12 mo 279 7.2
(6.0 to 8.4)
218 9.0
(7.3 to 10.7)
1.8
(−0.3 to 3.9)
96 7.0
(5.2 to 8.8)
−0.2
(−2.4 to 2.0)
420 5.8
(4.9 to 6.8)
−1.4
(−2.9 to 0.2)
24 mo 229 6.2
(5.3 to 7.1)
190 9.9
(7.4 to 12.4)
3.7
(1.0 to 6.4)
81 6.8
(4.9 to 8.6)
0.6
(−1.5 to 2.7)
379 5.2
(4.4 to 6.0)
−1.0
(−2.2 to 0.3)
a Missing data were imputed. PCSI domains6: scores range from0 to 100, with
higher score indicating more symptoms and dysfunction. Minimal clinically
important difference was not defined for this instrument.
bAmong active surveillance patients, 18.7% (54/289with available information)
received treatment within 24months: 6.2% for radical prostatectomy (n = 18),
6.9% for external beam radiotherapy (n = 20), 3.1% for brachytherapy (n = 9),
and 2.4% for other (n = 7).
c Unweighted numbers of patients with nonmissing data.
d Clinically meaningful difference was based on exceeding the threshold of 0.5
SD of the active surveillance baseline score. As reported in Table 1, SD scores
were 13.5 for urinary obstruction and irritation, 20.4 for urinary incontinence,
8.0 for bowel problems, and 37.6 for sexual dysfunction.
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Table 3. Propensity-Weighted Sexual, Urinary, and Bowel Function at 24Months by Treatment Type AmongMenWith Newly Diagnosed
Prostate Cancer, Stratified by Baseline Function Levela
No. of Patientsb
Function Level at 24 Months, % (95% CI)
Normalc Intermediated Poore
Sexual Dysfunction
Normal baseline level
Active surveillancef 67 44.6 (43.3-45.7) 30.3 (29.4-31.0) 25.2 (24.4-26.1)
Brachytherapy 16 36.2 (34.2-38.5) 29.6 (27.2-31.9) 34.2 (32.3-36.0)
Radical prostatectomy 130 9.4 (9.1-9.8) 33.5 (32.9-34.0) 57.1 (56.6-57.6)
External beam RT 47 27.1 (26.2-28.1) 45.7 (44.5-46.8) 27.2 (26.6-27.9)
Intermediate baseline level
Active surveillancef 64 10.2 (9.4-10.9) 43.9 (43.0-45.0) 45.9 (45.0-46.7)
Brachytherapy 20 2.7 (1.5-3.9) 46.7 (44.2-49.0) 50.6 (48.5-53.0)
Radical prostatectomy 111 5.1 (4.7-5.7) 18.0 (17.2-18.8) 76.9 (76.1-77.6)
External beam RT 46 6.6 (5.7-7.5) 38.4 (37.3-39.7) 55.0 (54.0-55.9)
Poor baseline level
Active surveillancef 96 2.6 (2.2-3.0) 10.1 (9.6-10.8) 87.2 (86.4-87.9)
Brachytherapy 41 1.3 (0.8-1.7) 20.3 (19.5-21.1) 78.5 (77.5-79.5)
Radical prostatectomy 132 1.0 (0.9-1.1) 4.3 (3.9-4.8) 94.7 (94.1-95.2)
External beam RT 96 1.2 (0.9-1.5) 13.8 (13.0-14.7) 85.0 (84.2-85.9)
Urinary Obstruction and Irritation
Normal baseline level
Active surveillancef 55 42.0 (41.1-42.8) 44.8 (43.8-45.7) 13.2 (12.4-14.1)
Brachytherapy 26 19.3 (17.8-20.9) 56.9 (54.8-58.6) 23.9 (22.4-25.3)
Radical prostatectomy 107 52.7 (52.3-53.2) 39.1 (38.6-39.6) 8.1 (7.7-8.6)
External beam RT 47 48.8 (48.0-49.5) 35.8 (34.8-36.7) 15.4 (14.5-16.4)
Intermediate baseline level
Active surveillancef 94 17.0 (16.4-17.6) 43.6 (42.7-44.5) 39.4 (38.6-40.2)
Brachytherapy 33 18.3 (17.0-19.5) 44.1 (42.1-46.1) 37.6 (36.2-39.0)
Radical prostatectomy 131 30.9 (29.4-32.3) 54.1 (52.5-55.9) 15.0 (14.2-15.9)
External beam RT 69 27.6 (26.7-28.6) 44.6 (43.6-45.5) 27.8 (26.8-28.7)
Poor baseline level
Active surveillancef 73 6.3 (5.6-7.0) 37.0 (36.1-38.0) 56.7 (55.8-57.7)
Brachytherapy 21 14.5 (13.6-15.4) 33.9 (32.1-35.9) 51.5 (50.3-52.8)
Radical prostatectomy 136 24.1 (23.3-24.8) 51.6 (50.8-52.4) 24.4 (23.8-24.9)
External beam RT 71 9.2 (8.5-9.9) 36.7 (35.8-37.7) 54.1 (53.2-54.8)
Urinary Incontinence
Normal baseline level
Active surveillancef 169 72.7 (71.8-73.5) 20.3 (19.6-21.0) 7.0 (6.7-7.4)
Brachytherapy 64 64.8 (63.7-65.8) 26.2 (25.2-27.2) 9.0 (8.3-9.7)
Radical prostatectomy 288 34.3 (33.7-34.8) 49.9 (49.2-50.6) 15.8 (15.4-16.3)
External beam RT 130 73.0 (72.3-73.7) 19.9 (19.3-20.5) 7.1 (6.6-7.4)
Intermediate baseline level
Active surveillancef 37 22.5 (21.1-23.7) 51.4 (49.4-53.4) 26.1 (24.6-27.6)
Brachytherapy 13 38.1 (34.7-41.7) 32.0 (27.4-36.6) 29.9 (26.7-33.4)
Radical prostatectomy 72 15.4 (14.5-16.2) 67.4 (66.4-68.3) 17.3 (16.6-17.8)
External beam RT 38 32.2 (31.0-33.6) 52.1 (51.0-53.3) 15.7 (14.8-16.6)
Bowel Problems
Normal baseline level
Active surveillancef 96 57.2 (56.2-58.2) 33.5 (32.3-34.8) 9.3 (8.7-9.9)
Brachytherapy 36 46.8 (45.1-48.4) 44.4 (42.7-46.4) 8.9 (7.6-10.5)
Radical prostatectomy 172 57.4 (56.3-58.2) 37.0 (36.1-38.0) 5.6 (5.2-6.0)
External beam RT 76 42.7 (41.8-43.5) 39.9 (39.2-40.5) 17.4 (16.7-18.2)
(continued)
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surveillance. Men who reported poor baseline sexual func-
tion largely remained with poor function at 24 months.
Urinary Obstruction and Irritation
At baseline, propensity-weighted scores were 22.8 (95% CI,
21.2 to 24.3) for active surveillance, 22.3 (95% CI, 20.3 to
24.4) for external beam radiotherapy, 20.8 (95% CI, 18.3 to
23.3) for brachytherapy, and 22.6 (95% CI, 21.1 to 24.2) for
prostatectomy (Table 2). Compared with active surveillance,
urinary obstruction and irritation scores increased after
brachytherapy at 3 and 12 months, but not 24 months (20.5
[95% CI, 15.1 to 25.9] at 3 months and 5.5 [95% CI, 0.4 to 10.6]
at 12 months), and increased after external beam radio-
therapy at 3 months (11.7 [95% CI, 8.7 to 14.8]). Patients who
received prostatectomy reported lower urinary obstruction
and irritation compared with active surveillance at 12 and 24
months (−4.3 [95% CI, −6.9 to −1.7] at 12 months and −5.7
[95% CI, −8.2 to −3.1] at 24 months). Score differences
between brachytherapy and external beam radiotherapy vs
active surveillance met the threshold for clinical significance
at 3 months.
Table 3 details 24-month outcomes in men with different
baseline urinary obstruction and irritation levels. For men at
normal baseline function, 52.7% remained at normal func-
tion at 24 months after prostatectomy, 48.8% after external
beam radiotherapy, and 19.3% after brachytherapy. For men
with baseline intermediate function for urinary obstruction
and irritation, 18.3% to 30.9% improved to normal function
after surgical or radiation treatments, whereas 15.0% to
37.6% worsened to poor function. At 24 months, most men
(75.7%) with poor baseline function for urinary obstruction
and irritation showed improvement after prostatectomy.
Among patients in other treatment groups with a poor func-
tion level at baseline of urinary obstruction and irritation,
45.9% improved after external beam radiotherapy, 48.5%
improved after brachytherapy, and 43.3% improved with ini-
tial active surveillance.
Urinary Incontinence
At baseline, propensity-weighted scores were 10.4 (95% CI,
8.2-12.8) for active surveillance, 9.9 (95% CI, 7.5-12.4)
for external beam radiotherapy, 10.5 (95% CI, 3.8-17.2) for
brachytherapy, and 9.7 (95% CI, 7.2-12.2) for prostatectomy
(Table 2). Incontinence scores were not significantly different
between external beam radiotherapy or brachytherapy vs
active surveillance at 3, 12, and 24months. For radical prosta-
tectomy vs active surveillance, incontinence scores increased
by 33.6 (95% CI, 27.8-39.2) at 3 months, 18.2 (95% CI, 12.9-
23.5) at 12 months, and 15.4 (95% CI, 8.9-21.9) at 24 months;
all of these differences were clinically significant.
For men with normal urinary control at baseline, 34.3%
reported normal control 24 months after prostatectomy,
whereas 15.8% reported poor control (Table 3). In other
groups, proportions of patients who maintained normal uri-
nary control at 24 months were 73.0% after external beam
radiotherapy, 64.8% after brachytherapy, and 72.7% after
active surveillance. For men with intermediate urinary con-
trol at baseline, 15.7% to 29.9% reported poor control at 24
months across the groups. Too few patients had a poor func-
tion level of urinary control at baseline (n = 50) for meaning-
ful analysis of that subgroup.
Bowel Problems
Atbaseline, propensity-weighted scoreswere5.9 (95%CI, 5.0-
6.8) for active surveillance, 5.7 (95% CI, 4.6-6.7) for external
beamradiotherapy,6.1 (95%CI,4.5-7.6) forbrachytherapy, and
6.2 (95% CI, 5.2-7.3) for prostatectomy (Table 2). Compared
with active surveillance, external beam radiotherapy in-
creased scores at 3 months (4.9 [95% CI, 2.4-7.4]) and 24
months (3.7 [95%CI, 1.0-6.4]).At 3months, thisdifferencewas
clinicallymeaningful. Scoresbetweenbrachytherapyandpros-
tatectomyvs active surveillancewere not significantly differ-
ent at any time point.
After external beam radiotherapy, 42.7% of men who
reported normal baseline function level also reported a nor-
mal function level at 24 months (Table 3). Corresponding
proportions were 46.8% after brachytherapy, 57.4% after
prostatectomy and 57.2% after active surveillance. In addi-
tion, 17.4% of patients who received external beam radio-
therapy who had a normal baseline function level worsened
to a poor function level at 24 months, whereas 5.6% to 9.3%
of patients in other groups worsened to poor function. Too
Table 3. Propensity-Weighted Sexual, Urinary, and Bowel Function at 24Months by Treatment Type AmongMenWith Newly Diagnosed
Prostate Cancer, Stratified by Baseline Function Levela (continued)
No. of Patientsb
Function Level at 24 Months, % (95% CI)
Normalc Intermediated Poore
Intermediate baseline level
Active surveillancef 102 28.9 (28.1-29.5) 54.8 (54.1-55.6) 16.3 (15.5-17.1)
Brachytherapy 36 27.0 (26.1-27.8) 56.9 (56.1-57.7) 16.2 (15.7-16.7)
Radical prostatectomy 161 34.8 (34.4-35.2) 50.5 (50.1-50.9) 14.7 (14.3-15.1)
External beam RT 80 19.9 (19.0-21.1) 60.3 (59.1-61.5) 19.8 (19.1-20.4)
Abbreviation: RT, radiotherapy.
a Missing data were imputed.
bUnweighted numbers of patients with nonmissing data.
c Normal function describes a patient with essentially no dysfunction or distress
in a domain.
d Intermediate function describes a patient with at least 1 distressful symptom
but none very distressful.
e Poor function describes a patient with at least 1 very distressful symptom.
f Among active surveillance patients, 18.7% received treatment within 24mo:
6.2% for radical prostatectomy, 6.9% for external beam RT, 3.1% for
brachytherapy, and 2.4% for other.
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few patients were at a poor function level at baseline for
meaningful analysis of that subgroup.
Discussion
Patients with prostate cancer have multiple treatment op-
tions and face a confusing decision-making process.
Therefore, the comparative effectiveness of contemporary
treatment options for localized prostate cancer is a top re-
search priority according to the National Academy of Med-
icine.1 Although contemporary treatments (robotic surgery,
intensity-modulated radiotherapy) were developed to re-
duce treatment-relatedmorbidity, the comparative effective-
ness of these treatments vs active surveillance is unknown.
A population-based cohort can be used to inform this ques-
tionbyproviding timelydata frompatientswhoare represen-
tative of men with prostate cancer. This study addresses one
aspect of this comparative effectiveness question by showing
that contemporary treatment options were associated with
distinct patterns of QOL changes. These data may help in-
form men in their treatment decision-making process, and
also inform the continued debate regarding prostate cancer
screening. The US Preventive Services Task Force, in the cur-
rent process of revising its screening recommendations,
specifically indicated a need to review the harms of different
treatment approaches.21 This study directly addresses this
knowledge gap.
In light of recently published data from the Prostate Test-
ing for Cancer and Treatment (ProtecT) trial,4 this study pro-
vides new information. This is because the ProtecT trial
started in 1999 and used older treatments (3-dimensional
radiotherapy, nonrobotic prostatectomy) that may have lim-
ited relevance to informing contemporary patients regarding
current treatment options, which consist of intensity-
modulated radiotherapy,2 robotic prostatectomy,22 and
brachytherapy.23 The current study provides QOL outcomes
of treatments representative of contemporary choices for
patients; the surgical and radiotherapy treatments received
by patients in this study (86.6% robotic prostatectomy,
94.8% intensity-modulated radiotherapy) are reflective of
treatment patterns in the United States.2,22 With advances in
both surgical and radiotherapy technologies, the relative QOL
results across treatment groups remain similar as those
reported by the ProtecT trial: radical prostatectomywas asso-
ciated with sexual dysfunction and urinary incontinence,
whereas radiotherapy was associated with short-term uri-
nary obstruction and irritation and bowel symptoms.
Active surveillance is an emerging option for men with
early prostate cancers,5 and served as a natural control group
for this study, to help inform the decision for men consider-
ing this option vs immediate treatment. This study showed
that mean QOL scores for this group remained at baseline lev-
els, until 12 months and after when urinary incontinence and
sexual dysfunction scores noticeably increased. This coin-
cides with the timing of guideline-recommended repeat
prostate biopsies on active surveillance, with each biopsy
expected to detect a proportion of patients with cancer pro-
gression necessitating treatment. Although surveillance is
the most conservative option, it is notable that mean QOL
scores at 24 months were not clinically meaningfully differ-
ent between this group and active treatment groups in most
domains. This observation can be explained by the gradual
progression of men on surveillance to treatment over time,
whereas men who received immediate treatment experi-
enced gradual improvement in treatment-related symptoms.
These findings are consistent with those from the ProtecT
trial24 and provide information that can be used to help
counsel patients—and demonstrates that, on average, active
surveillance may be associated with preserved QOL, at least
in the first 2 years after diagnosis.
Although QOL research conventionally reports results
usingmean scores, it iswell recognized that score changes are
difficult to interpretbypatientsandphysicians.10,12 Several ap-
proaches have been proposed to address this interpretability
challenge, including definition of aminimal clinically impor-
tant difference or using an arbitrary 0.5-SD change to denote
clinicallymeaningful change.17,18A limitationof thePCSI is that
it doesnot have adefinedminimal clinically important differ-
ence throughananchor-basedmethod, and thereforewe took
the latter approach in this study. It is alsowell established that
menwithdifferent levelsofbaselineurinary,bowel, andsexual
function likelyhavedifferentexperiencesafter treatment.9For
example,menwith no useful erectile function at baseline are
unlikely to experience anymeaningful positive ornegative ef-
fect of their sexual function fromtreatment; therefore, includ-
ing thesemen inoverallmeanscore calculationsblunts theob-
served effect (score changes) experienced by other men who
have normal baseline function. The PCSI is unique among ex-
istingprostatecancerQOL instruments inhavingdefined func-
tional levels, which provides a framework for defining clini-
cally meaningful change and also allows stratification of
patientsbybaseline function.Thus, anadditional analysiswas
performed using QOL levels established by the PCSI instru-
ment to complement the reported mean scores.
Physicians can use these data to provide more individu-
alized counseling of their patients regarding expected out-
comes of patientswith similar levels of baseline function. For
example, among men with normal sexual function at base-
line, 57.1%were estimated tohavepoor function at 24months
after prostatectomy; 9% of patients reported preserved nor-
mal function, whereas the other one-third experienced de-
clined but still useful sexual function. Men who chose active
surveillance had the largest proportion (44.6%) with pre-
served normal sexual function at 24 months.
These data also revealed that some QOL aspects can im-
proveafter treatment.Oldermencommonlyhavebenignpros-
tatic hypertrophy with associated urinary obstructive symp-
toms, which can be improved by prostate cancer treatments.
In the group of men who had an intermediate-level of base-
line urinary obstruction and irritation symptoms, prostatec-
tomy improved symptoms by 24 months in more patients
(30.9%) than worsened (15.0%), and external beam radio-
therapy improved and worsened similar proportions. These
findings are consistent with prior studies.25,26 There are ad-
ditional possible reasons for some patients experiencing
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improvements inurinary symptoms—includingmedicalman-
agement of symptoms and surgical and radiation treatments
alleviating symptoms caused by the prostate cancer itself.
There are several strengthsof this study. Studydesignwas
informedbycollaborationwithabroadgroupofstakeholders,20
with the goal that this study will provide information rel-
evant to patients and clinicians. This study compared the 4
treatment options most relevant to contemporary patients.
However, randomized data suggest that short-term QOL be-
tween open vs robotic prostatectomy are not significantly
different.27 Population-baseddesign facilitated a sociodemo-
graphically diverse cohort including patients who chose ac-
tive surveillance, and not just patients treated at large aca-
demic centers. Another strength is that 100% of patients
reported pretreatment QOL without recall, which allows ac-
curate calculations of treatment effect. The study also uti-
lizedaconsistentmethodology forQOLassessmentusing tele-
phone survey7 and timepoints based on treatment date,with
measurements that captured both short-term (3-month) and
longer-term changes.
There are several limitations of this study. As an observa-
tional study, which is descriptive in nature, there were imbal-
ances in baseline patient characteristics. Propensity weight-
ing was used to minimize these imbalances across groups,
but residual confounding is possible and there remained
unbalanced disease characteristics across groups with favor-
able characteristics for active surveillance patients and rela-
tively less favorable characteristics for external beam radio-
therapy. Patients were not blinded to treatment received, and
patient expectations regarding outcomes from the treatment
they received could affect their reporting of QOL. Enrollment
in the study was only 57%, which could have led to a selec-
tion bias, although this was not out of the range of other
studies.28 There was missing data especially with longer
follow-up (19%-29% at 24-month time point), with differen-
tial response rates across groups. In addition, participants
were recruited from 1 state. However, they were broadly rep-
resentative of men with prostate cancer: the median age of
NC ProCESS participants (66 years) was similar to prostate
cancer patients across the United States,29 and the types of
radiation (94.8% intensity-modulated radiation therapy) and
surgical treatments (86.6% robotic) received were similar to
US patterns of care studies.2,22 Also, the Rapid Case Ascer-
tainment system of North Carolina facilitated all participants
to be enrolled prior to treatment. This study assessed sexual,
urinary, and bowel symptoms, which are most commonly
affected after prostate cancer treatments, but did not assess
general QOL. In addition, QOL may continue to change more
than 2 years after treatment. This analysis included results
only through 2 years of follow-up, and further follow-up is
ongoing. However, as the ProtecT trial showed,4 theremay be
little change in QOL after 2 years.
Conclusions
In this cohortofmenwith localizedprostate cancer, each treat-
ment strategywas associatedwith distinct patterns of adverse
effectsover2years.Thesefindingscanbeusedtopromotetreat-
ment decisions that incorporate individual preferences.
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